SVB Wealth LLC Has $2.65 Million Holdings in Pfizer Inc. $PFE

SVB Wealth LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 20.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 94,319 shares of the biopharmaceutical company’s stock after selling 23,728 shares during the period. SVB Wealth LLC’s holdings in Pfizer were worth $2,648,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Norges Bank bought a new position in shares of Pfizer during the 4th quarter valued at about $1,830,986,000. Morgan Stanley raised its holdings in Pfizer by 19.2% during the 4th quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the period. Bank of New York Mellon Corp raised its holdings in Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the period. Franklin Resources Inc. lifted its stake in Pfizer by 47.8% in the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company’s stock valued at $638,787,000 after buying an additional 8,108,887 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Pfizer by 577.5% in the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock valued at $218,817,000 after buying an additional 7,489,189 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Negative Sentiment: Pfizer reported that its experimental lung cancer treatment, sigvotatug vedotin, missed the main goal in a late-stage Phase 3 trial, a setback that raises questions about the drug’s commercial prospects and the strength of the company’s oncology pipeline. Article: Pfizer’s experimental drug misses main goal of lung cancer trial
• Negative Sentiment: Investors are also digesting leadership turnover after Pfizer said CFO Dave Denton will step down effective August 15, which adds near-term uncertainty around financial leadership. Article: Pfizer (PFE) CFO Dave Denton to Step Down Effective August 15
• Neutral Sentiment: Pfizer said it is not planning a major acquisition in the next couple of years and instead wants to use artificial intelligence to improve operations, signaling a focus on internal efficiency rather than M&A-driven growth. Article: Pfizer Isn’t Expecting to Make Any Big Acquisition in the Next Couple of Years, but It’s Planning to Do This Instead
• Neutral Sentiment: Broader commentary around Pfizer’s valuation, dividend appeal, and obesity-drug strategy may be supporting longer-term investor interest, but these pieces are not likely the main driver of the stock’s move today. Article: Eli Lilly vs Pfizer: One Owns the Obesity Market Today, The Other Paid to Compete Tomorrow

Pfizer Stock Performance

Shares of PFE stock opened at $25.07 on Tuesday. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75. The company’s fifty day simple moving average is $26.18 and its 200-day simple moving average is $26.33. The firm has a market cap of $142.87 billion, a PE ratio of 19.14 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the firm earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 131.30%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. HSBC upped their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Monday, March 2nd. UBS Group reissued a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a report on Monday, March 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $28.82.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.